Shares of ASCENTAGE PHARMA GROUP - B (06855) climbed more than 3% during the trading session. At the time of writing, the stock was up 1.38%, trading at HK$45.88, with a turnover of HK$36.975 million.

According to information from pharmaceutical observers, on February 2nd, the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) announced that the Class 1 new drug APG-3288 tablets, submitted by ASCENTAGE PHARMA GROUP, has been approved for clinical trials. The intended development is for the treatment of relapsed/refractory hematologic malignancies. Public information indicates this is a new-generation BTK-targeted protein degradation therapy developed by ASCENTAGE PHARMA GROUP. The product had already received clinical trial approval in the United States this past August, with plans to develop it for treating relapsed/refractory B-cell malignancies.

APG-3288 is the first novel, highly potent, and selective BTK degrader independently developed by ASCENTAGE PHARMA GROUP. This molecule works by promoting the formation of a ternary complex, subsequently leading to the degradation of BTK via the proteasome. Preclinical research results show that, compared to other investigational BTK degraders, APG-3288 possesses stronger BTK degradation capability, higher selectivity, and superior pharmacokinetic (PK) characteristics, demonstrating significant potential.